MEP23608A - Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative - Google Patents

Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative

Info

Publication number
MEP23608A
MEP23608A MEP-236/08A MEP23608A MEP23608A ME P23608 A MEP23608 A ME P23608A ME P23608 A MEP23608 A ME P23608A ME P23608 A MEP23608 A ME P23608A
Authority
ME
Montenegro
Prior art keywords
biotin
polysaccharides
covalent bond
antithrombotic activity
derivative
Prior art date
Application number
MEP-236/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Philippe Duchaussoy
Jean-Marc Herbert
Maurice Petitou
Pierre Savi
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MEP23608A publication Critical patent/MEP23608A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MEP-236/08A 2000-09-22 2001-09-20 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative MEP23608A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0012094A FR2814463B1 (fr) 2000-09-22 2000-09-22 Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
YUP-197/03A RS50730B (sr) 2000-09-22 2001-09-20 Polisaharidi sa antitrombičkom aktivnošću koji sadrže najmanje jednu kovalentnu vezu sa biotinom ili derivatom biotina
PCT/FR2001/002918 WO2002024754A1 (fr) 2000-09-22 2001-09-20 Polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine

Publications (1)

Publication Number Publication Date
MEP23608A true MEP23608A (en) 2010-06-10

Family

ID=8854579

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2008-236A ME00080B (me) 2000-09-22 2001-09-20 Polisaharidi sa antitrombičkom aktivnošću koji sadrže najmanje jednu kovalentnu vezu sa biotinom ili derivatom biotina
MEP-236/08A MEP23608A (en) 2000-09-22 2001-09-20 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2008-236A ME00080B (me) 2000-09-22 2001-09-20 Polisaharidi sa antitrombičkom aktivnošću koji sadrže najmanje jednu kovalentnu vezu sa biotinom ili derivatom biotina

Country Status (40)

Country Link
US (3) US6844329B2 (cs)
EP (1) EP1322673B1 (cs)
JP (2) JP5016778B2 (cs)
KR (2) KR20080049139A (cs)
CN (1) CN1235914C (cs)
AR (1) AR030774A1 (cs)
AT (1) ATE374215T1 (cs)
AU (2) AU2001291960C1 (cs)
BG (1) BG66191B1 (cs)
BR (1) BR0114007A (cs)
CA (1) CA2418815C (cs)
CY (1) CY1108076T1 (cs)
CZ (1) CZ300856B6 (cs)
DE (1) DE60130669T2 (cs)
DK (1) DK1322673T3 (cs)
EA (1) EA005133B1 (cs)
EC (1) ECSP034514A (cs)
EE (1) EE05202B1 (cs)
ES (1) ES2292625T3 (cs)
FR (1) FR2814463B1 (cs)
GE (1) GEP20053616B (cs)
HK (1) HK1053316A1 (cs)
HR (1) HRP20030219B1 (cs)
HU (2) HUP0303551A3 (cs)
IL (2) IL154848A0 (cs)
IS (1) IS2550B (cs)
ME (2) ME00080B (cs)
MX (1) MXPA03002483A (cs)
NO (2) NO332905B1 (cs)
NZ (1) NZ524472A (cs)
PE (1) PE20020471A1 (cs)
PL (1) PL206727B1 (cs)
PT (1) PT1322673E (cs)
RS (1) RS50730B (cs)
SI (1) SI1322673T1 (cs)
SK (2) SK287218B6 (cs)
TW (1) TWI308153B (cs)
UA (1) UA79736C2 (cs)
WO (1) WO2002024754A1 (cs)
ZA (1) ZA200301692B (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
FR2874924B1 (fr) * 2004-09-09 2006-12-01 Sanofi Aventis Sa Hexadecasaccharides biotinyles, leur preparation et leur utilisation therapeutique
TWI403334B (zh) * 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
ES2362011T3 (es) * 2005-10-10 2011-06-27 N.V. Organon Inhibidores duales antitrombóticos anticoagulantes que comprenden una marca de biotina.
BRPI0617215A2 (pt) * 2005-10-10 2011-07-19 Organon Nv composto anti-trombótico, composição farmacêutica, e, uso do composto
CN1317035C (zh) * 2005-10-24 2007-05-23 天津大学 基于酰肼基的微粒表面多重生物功能因子组装方法
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
FR2912409B1 (fr) * 2007-02-14 2012-08-24 Sanofi Aventis Heparines de bas poids moleculaire comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine leur procede de preparation,leur utilisation
TW201006479A (en) * 2008-07-18 2010-02-16 Sanofi Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2233143A1 (en) 2009-03-24 2010-09-29 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2145624A1 (en) 2008-07-18 2010-01-20 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
FR2935386B1 (fr) 2008-08-26 2010-09-10 Sanofi Aventis Nouveaux polysaccharides a activite antithrombotique comprenant une liaion covalente avec une chaine amine
EP2323605A4 (en) * 2008-09-10 2014-02-05 Syneron Medical Ltd TRANSDERMAL RELEASE OF OLIGOSACCHARIDES
CA2746509C (en) 2008-12-19 2018-11-20 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of impulsive agression
FR2952935B1 (fr) * 2009-11-20 2011-12-02 Sanofi Aventis Procede de preparation du n-biotinyl-6-aminocaproate de n succinimidyle
AU2010332797B2 (en) 2009-12-18 2015-05-28 Catalent Pharma Solutions Gmbh Pharmaceutical oral dosage form containing a synthetic oligosaccharide
CZ302669B6 (cs) * 2010-03-29 2011-08-24 Univerzita Palackého v Olomouci Efektivní zpusob biotinylace aminosloucenin pomocí syntézy na pevné fázi pro potreby afinitní chromatografie
CZ302510B6 (cs) * 2010-03-29 2011-06-22 Univerzita Palackého v Olomouci Efektivní zpusob biotinylace sloucenin s karboxylovou skupinou pomocí syntézy na pevné fázi pro potreby afinitní chromatografie
AU2011235222B2 (en) 2010-03-31 2014-09-25 Supernus Pharmaceuticals Inc. Stabilized formulations of CNS compounds
FR2964660B1 (fr) * 2010-09-10 2012-09-28 Sanofi Aventis Nouveaux polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree
JP2013537181A (ja) * 2010-09-10 2013-09-30 サノフイ 抗血栓活性及び改善された代謝安定性を有するビオチン化多糖類
EP2484366A1 (en) 2011-02-07 2012-08-08 Sanofi Idrabiotaparinux for the treatment of pulmonary embolism and for the secondary prevention of venous thromboembolic events
ES2560467T3 (es) 2011-06-17 2016-02-19 Carbomimetics Pentasacáridos sintéticos que tienen vida media corta y alta actividad
EP3524251A1 (en) * 2012-11-13 2019-08-14 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
WO2015195404A1 (en) 2014-06-20 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detection of an analyte by movement of tethered microparticles
WO2016205239A1 (en) 2015-06-15 2016-12-22 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Non-hormonal mammalian sperm decoy contraception based on the n-terminus of the zp2 protein
JP7492826B2 (ja) 2016-10-21 2024-05-30 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 分子ナノタグ
CN108976318B (zh) * 2017-06-01 2021-03-30 首都医科大学 单-6-(生物素酰胺基)-6-脱氧-β-环糊精及其制备方法和应用
WO2019133727A1 (en) 2017-12-29 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Universal influenza virus probe set for enrichment of any influenza virus nucleic acid
BR112022000255A8 (pt) 2019-07-09 2022-03-22 Optimvia Llc Métodos para sintetizar polissacarídeos anticoagulantes
WO2021075165A1 (ja) * 2019-10-17 2021-04-22 株式会社オートネットワーク技術研究所 配線モジュール
WO2022056078A1 (en) 2020-09-11 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rnase h-assisted detection assay for rna (radar)
WO2024191684A1 (en) 2023-03-10 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection of hepatitis c virus ribonucleic acid from whole blood using reverse transcription loop-mediated isothermal amplification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960884A (en) * 1974-04-24 1976-06-01 Sergei Ivanovich Zavyalov Method of preparing racemic biotin
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
IL102758A (en) * 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
FR2751334B1 (fr) * 1996-07-19 1998-10-16 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
FR2773804B1 (fr) * 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
GB2335490B (en) * 1998-03-20 2003-05-14 Ortho Clinical Diagnostics An assay surface that permits an analyte releasiing step
AU8366398A (en) * 1998-07-07 2000-01-24 Department Of Radiation Oncology University Of Washington Trifunctional reagent for conjugation to a biomolecule
WO2000006608A1 (fr) 1998-07-31 2000-02-10 Seikagaku Corporation Nouveau glycosaminoglycan et compositions medicamenteuses le contenant
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine

Also Published As

Publication number Publication date
NO20031295D0 (no) 2003-03-20
AU9196001A (en) 2002-04-02
DK1322673T3 (da) 2008-01-14
EP1322673A1 (fr) 2003-07-02
CA2418815A1 (en) 2002-03-28
PL206727B1 (pl) 2010-09-30
EP1322673B1 (fr) 2007-09-26
HRP20030219A2 (en) 2003-06-30
ZA200301692B (en) 2004-03-01
IL154848A (en) 2010-11-30
HUP0303551A3 (en) 2004-03-29
HRP20030219B1 (en) 2011-10-31
US6844329B2 (en) 2005-01-18
MXPA03002483A (es) 2004-05-24
EE200300114A (et) 2005-02-15
PT1322673E (pt) 2007-12-03
CY1108076T1 (el) 2014-02-12
SK287054B6 (sk) 2009-10-07
SK287218B6 (sk) 2010-03-08
CN1466594A (zh) 2004-01-07
BG107650A (bg) 2003-11-28
WO2002024754A1 (fr) 2002-03-28
EE05202B1 (et) 2009-08-17
NO20110401L (no) 2003-05-22
US7943595B2 (en) 2011-05-17
US20060160768A1 (en) 2006-07-20
US20040024197A1 (en) 2004-02-05
EA005133B1 (ru) 2004-12-30
FR2814463B1 (fr) 2002-11-15
CA2418815C (en) 2011-05-10
SK3562003A3 (en) 2003-11-04
TWI308153B (en) 2009-04-01
BG66191B1 (bg) 2011-12-30
ATE374215T1 (de) 2007-10-15
YU19703A (sh) 2006-05-25
BR0114007A (pt) 2003-08-12
HK1053316A1 (en) 2003-10-17
GEP20053616B (en) 2005-09-26
JP5016778B2 (ja) 2012-09-05
KR20080049139A (ko) 2008-06-03
NO20031295L (no) 2003-05-22
PL363368A1 (en) 2004-11-15
ME00080B (me) 2010-10-10
DE60130669T2 (de) 2008-07-17
WO2002024754A8 (fr) 2003-07-03
NO332905B1 (no) 2013-01-28
NZ524472A (en) 2004-10-29
EA200300237A1 (ru) 2003-08-28
CZ300856B6 (cs) 2009-08-26
IL154848A0 (en) 2003-10-31
IS6733A (is) 2003-02-28
CN1235914C (zh) 2006-01-11
ECSP034514A (es) 2003-04-25
JP2004509902A (ja) 2004-04-02
PE20020471A1 (es) 2002-06-01
CZ2003814A3 (cs) 2003-06-18
AU2001291960B2 (en) 2007-03-01
JP2012131809A (ja) 2012-07-12
ES2292625T3 (es) 2008-03-16
FR2814463A1 (fr) 2002-03-29
HU1400034D0 (hu) 2004-03-01
AR030774A1 (es) 2003-09-03
KR20030055269A (ko) 2003-07-02
HUP0303551A2 (hu) 2004-03-01
DE60130669D1 (de) 2007-11-08
SI1322673T1 (sl) 2008-02-29
IS2550B (is) 2009-10-15
US20110144042A1 (en) 2011-06-16
US8318696B2 (en) 2012-11-27
AU2001291960C1 (en) 2009-10-08
KR100891388B1 (ko) 2009-04-02
RS50730B (sr) 2010-08-31
UA79736C2 (uk) 2007-07-25

Similar Documents

Publication Publication Date Title
MEP23608A (en) Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative
HN1999000125A (es) Nuevos derivados sustituidos del pirazol
ME00601B (me) Modified factor viii
HN1998000057A (es) Derivados de nicotinamida
TR200003036T2 (tr) 12,13-Modifiye edilmiş epotilon türevleri
ATE264863T1 (de) 28-epirapaloge
EA200100022A1 (ru) Композиции с контролируемым высвобождением пароксетина
DK1282663T3 (da) Gel af et poly-a-1,4-glucan og stivelse
DE60135967D1 (de) Promotoren, die auf Umweltstress reagieren
MEP36808A (en) Ambroxol-containing lozenge
BR9813465A (pt) Polissacarìdeos modificados que exibem reconhecimento biológico alterado
BR0009469A (pt) Tablete perfumado de detergente
BR0114065A (pt) Triazolo-epotilonas
IT1303534B1 (it) Procedimento per controllare i riporti di adesivo sui fondi aperti disacchi o borse.
GT200000053S (es) Diseño de cabeza de cepillo de dientes.
ATE295746T1 (de) Radioaktiv beschichtete stents
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ES2196802T3 (es) Lactatos de citronelilo y/o de dihidrocitronelilo, su preparacion y su utilizacion.
TR199902605T2 (xx) Fibrinojenin azalt�lma y�ntemleri.
DOP2000000050A (es) Composición antidecoloracion
HN1999000201A (es) Derivados de 3,3 biarilpiperidina y 2,2 - biarilmorfolina
SU1727243A3 (ru) Дезинфицирующее средство
ES1027501Y (es) Elemento de cristaleria con musica incorporada.
ES1046845U (es) Alcorque.
RS50474B (sr) Postupak izrade supstituisanih 8-arilhinolinijum benzensulfonata